RU2019116624A - Новые анти_cd137 антитела и их применение - Google Patents
Новые анти_cd137 антитела и их применение Download PDFInfo
- Publication number
- RU2019116624A RU2019116624A RU2019116624A RU2019116624A RU2019116624A RU 2019116624 A RU2019116624 A RU 2019116624A RU 2019116624 A RU2019116624 A RU 2019116624A RU 2019116624 A RU2019116624 A RU 2019116624A RU 2019116624 A RU2019116624 A RU 2019116624A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| GB1619648.7 | 2016-11-21 | ||
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019116624A true RU2019116624A (ru) | 2020-12-21 |
| RU2019116624A3 RU2019116624A3 (cg-RX-API-DMAC10.html) | 2021-01-29 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019116624A RU2019116624A (ru) | 2016-11-21 | 2017-11-21 | Новые анти_cd137 антитела и их применение |
Country Status (14)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| US10174122B2 (en) * | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc. | anticorpos anti-cd137 e métodos de uso dos mesmos |
| CR20200042A (es) * | 2017-08-01 | 2020-03-03 | Lilly Co Eli | Anticuerpos anti-cd137 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN112020517B (zh) | 2018-03-23 | 2024-10-29 | 伊莱利利公司 | 用于与抗pd-l1抗体组合的抗cd137抗体 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| MX2021001431A (es) * | 2018-08-10 | 2021-05-12 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso. |
| CN112739718B (zh) * | 2018-09-12 | 2024-11-26 | 祐和医药科技(北京)有限公司 | 抗tnfrsf9抗体及其用途 |
| US12227582B2 (en) | 2019-01-02 | 2025-02-18 | Qlsf Biotherapeutics Inc. | CD137 agonist antibodies and uses thereof |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| BR112021026309A2 (pt) | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| KR20220087479A (ko) * | 2019-11-13 | 2022-06-24 | 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 | 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용 |
| MX2022008412A (es) | 2020-01-07 | 2022-08-08 | Univ Texas | Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer. |
| KR20220132555A (ko) | 2020-01-29 | 2022-09-30 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용 |
| KR20220133238A (ko) | 2020-01-29 | 2022-10-04 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도 |
| JP7715722B2 (ja) * | 2020-02-28 | 2025-07-30 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｃｄ１３７コンストラクト及びその使用 |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| WO2022002063A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 一种4-1bb结合蛋白及其应用 |
| KR20230129484A (ko) * | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 4-1bb와 특이적으로 결합하는 항체 및 그 항원 결합단편 |
| JP2024522234A (ja) | 2021-06-18 | 2024-06-11 | アリゲーター・バイオサイエンス・アーベー | 新規な併用療法及びその使用 |
| US20250084155A1 (en) | 2021-09-29 | 2025-03-13 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
| WO2023126821A1 (en) * | 2021-12-29 | 2023-07-06 | Curateq Biologics Private Limited | C1q binding assay |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4789724A2 (en) * | 2022-09-22 | 2026-08-12 | ABlink Biotech Co., Ltd. | Anti-4-1bb nanobody 137-7, preparation therefor, and use thereof |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| TWI423814B (zh) | 2006-09-01 | 2014-01-21 | Genticel | 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子 |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| BR112017024770A2 (pt) * | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 BR BR112019010265-5A patent/BR112019010265A2/pt active IP Right Grant
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
-
2022
- 2022-11-10 US US18/054,373 patent/US12509526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190352414A1 (en) | 2019-11-21 |
| GB201619648D0 (en) | 2017-01-04 |
| KR20190086691A (ko) | 2019-07-23 |
| CN109963873B (zh) | 2023-12-26 |
| US11535678B2 (en) | 2022-12-27 |
| AU2017360094B2 (en) | 2024-12-12 |
| IL266738B1 (en) | 2024-02-01 |
| US12509526B2 (en) | 2025-12-30 |
| WO2018091740A2 (en) | 2018-05-24 |
| NZ754051A (en) | 2023-05-26 |
| IL266738B2 (en) | 2024-06-01 |
| US10689454B2 (en) | 2020-06-23 |
| BR112019010265A2 (pt) | 2019-09-17 |
| US20190352411A1 (en) | 2019-11-21 |
| WO2018091740A3 (en) | 2018-06-28 |
| US20230295325A1 (en) | 2023-09-21 |
| MX2019005911A (es) | 2019-07-08 |
| JP2020501531A (ja) | 2020-01-23 |
| AU2017360094A1 (en) | 2019-06-20 |
| EP3541844A2 (en) | 2019-09-25 |
| KR102679632B1 (ko) | 2024-06-28 |
| IL266738A (en) | 2019-07-31 |
| JP7068303B2 (ja) | 2022-05-16 |
| RU2019116624A3 (cg-RX-API-DMAC10.html) | 2021-01-29 |
| CA3044339A1 (en) | 2018-05-24 |
| CN109963873A (zh) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501531A5 (cg-RX-API-DMAC10.html) | ||
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| TWI771361B (zh) | 人程序性死亡受體pd-1的單株抗體及其片段 | |
| DK2430051T3 (en) | Compositions containing antibodies for the treatment of CD5 + HLA-DR + B- or T-cell-related diseases | |
| CA3114467C (en) | Anti pd-l1 antibody and use thereof | |
| JP2013502913A5 (cg-RX-API-DMAC10.html) | ||
| BR112021009325A2 (pt) | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica | |
| CN109790223A (zh) | 用于治疗癌症的抗siglec-7抗体 | |
| CN115960230A (zh) | 靶向分子的抗原结合构建体 | |
| JP2014527814A5 (cg-RX-API-DMAC10.html) | ||
| EP4001308A1 (en) | Anti-tigit antibodies and application thereof | |
| CN102209730A (zh) | 抗cxcr4抗体及其用于治疗癌症的用途 | |
| WO2015075725A1 (en) | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy | |
| JP2024016024A5 (cg-RX-API-DMAC10.html) | ||
| JP2022553851A5 (cg-RX-API-DMAC10.html) | ||
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| AU2020225173A1 (en) | Anti-PD-L1 antibody and use thereof | |
| KR20230028386A (ko) | 인간 질환의 치료를 위한 cd38 항체 | |
| AU2018382966A1 (en) | Use of a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist in a dosage regime to treat cancer | |
| CA3215704A1 (en) | Antibodies binding trop2 and uses thereof | |
| JP2025516590A5 (cg-RX-API-DMAC10.html) | ||
| KR20240004837A (ko) | 항-5t4 항체 및 이의 용도 | |
| JP5884139B2 (ja) | Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬 | |
| WO2019102456A1 (en) | Immunotoxins for treating cancer | |
| JP2024522234A5 (cg-RX-API-DMAC10.html) |